ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1547

Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)

Jun Won Park1, Jin Kyun Park1, Kichul Shin2, Yong-Beom Park3, Eun Bong Lee1, Yeong Wook Song4 and Eun Young Lee1, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 2Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), 3Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Ankylosing spondylitis (AS), drug therapy, Spondylarthritis and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)

Methods: This observational cohort study was based on prospectively registered data of nationwide KOBIO registry. A total of 776 SpA patients with available data and more than one year of TNFi adherence were included. Quantification of TNFi dosage were expressed using dose-quotient (DQ), which was calculated as ¡®(actual prescribed dose/standard dose) x (standard dosing interval/actual dosing interval)¡¯ annually. We used linear mixed model to estimate the change in disease activity (ASDAS-CRP, BASDAI and BASFI) over 3 years between the two strategies. Classifying as dose-tapering was based on both mean DQ of patients (individual level) and DQs of all 1-year observations from all patients (time level). Incidence of discontinuation of TNFi due to inefficacy and adverse event were also compared.

Results: At the individual level, patients with mean DQ<1.0 (tapering group, n=322) were more likely to have obesity (33.5% vs. 29.4%, p<0.001) and be first TNFi users (82.9% vs. 75.1%, p=0.009) and showed higher CRP level (2.6¡¾3.1 vs. 2.1¡¾2.6 mg/dL, p=0.039) than those with standard-dose TNFi (standard-dose group, n=454). Other baseline clinical factors including age, gender, smoking status, HLA-B27 positivity, and disease activity were comparable. Change in ASDAS-CRP over time in the tapering group was not significantly different from that in the standard-dose group (p value for time*group=0.872). This result was consistent after adjustment for baseline factors (age, obesity, HLS-B27 and definite sacroiliitis) which showed relevant interaction with ASDAS-CRP changes (figure 1). At the time level, 186 (24.0%), 204 (35.6%) and 95 (41.9%) patients received reduced dose of TNFi during 0~1, 1~2 and 2~3-year period, respectively. There was no significant interaction between yearly DQ and relevant ASDAS-CRP change (p value for time*DQ=0.435) (figure 2). In the multivariable model, difference in ASDAS-CRP between the standard-dose TNFi and tapering TNFi over the entire follow-up was 0.10 (95% CI=-0.01 to 0.21). Two treatment strategies showed comparable efficacy regarding BASDAI and BASFI. Incidences of drug discontinuation due to inefficacy and adverse events between the two groups were also comparable (figure 2).

Conclusion: In SpA patients with at least one year of TNFi adherence, dose-tapering of TNFi showed a comparable clinical efficacy to standard-dose TNFi treatment.


Disclosure: J. W. Park, None; J. K. Park, None; K. Shin, None; Y. B. Park, None; E. B. Lee, Green Cross Corp, 2,Pfizer Inc, 5; Y. W. Song, None; E. Y. Lee, None.

To cite this abstract in AMA style:

Park JW, Park JK, Shin K, Park YB, Lee EB, Song YW, Lee EY. Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/dose-tapering-of-tnfi-in-patients-with-axial-spondyloarthritis-an-observational-cohort-study-from-nationwide-korean-college-of-rheumatology-biologic-registry-kobio/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dose-tapering-of-tnfi-in-patients-with-axial-spondyloarthritis-an-observational-cohort-study-from-nationwide-korean-college-of-rheumatology-biologic-registry-kobio/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.